Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
$1.38
$0.01(0.54%)
At close: 4:00 PM EST
$1.38
$0.01(0.54%)
Day’s Range― - ―
52-Week Range$0.40 - $2.27
Previous CloseN/A
Volume579.15K
Average Volume (3M)670.12K
Market Cap
$78.18M
Enterprise Value-$40.95M
Total Cash (Recent Filing)$60.63M
Total Debt (Recent Filing)$4.35M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Mar 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding53,551,132
10 Day Avg. Volume555,214
30 Day Avg. Volume670,121
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-0.71
Enterprise Value/Market Cap-0.52
Enterprise Value/Revenue-47.17
Enterprise Value/Gross Profit-1.28K
Enterprise Value/Ebitda0.38
Forecast
1Y Price Target
$2.00Price Target Upside44.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial DesignALX Oncology is updating the design of its Phase 2 ASPEN-Breast study to enable a CD47 and HER2 biomarker-driven strategy, which could enhance the trial's effectiveness.
High-Priority ProgramsThe anti-EGFR ADC, ALX2004, remains a high-priority program with significant potential, and the clinical program is on track to begin with the first patient expected to be dosed imminently.
Market OpportunityData suggests that 50-70% of HER2+ breast cancer patients overexpress CD47, representing a large market opportunity for ALX Oncology if the study is successful.
Bears Say
Resource PrioritizationALX has decided not to move forward with the planned Phase 1 ASPEN-CRC study, indicating a need to better prioritize cash resources.
Trial Design ChallengesThe single-arm design of the new study may make the data more difficult to interpret compared to the prior plan for a randomized control trial.
Trial PausingThe ASPEN-CRC trial of Evo in colorectal cancer has been paused to focus development on breast cancer, reflecting a shift in priorities.
ALX Oncology Holdings News
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.40 and its highest was $2.27 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $78.18M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is Mar 05, 2026 which is in 116 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Nov 07, 2025. The company reported -$0.365 earnings per share for the quarter, beating the consensus estimate of -$0.367 by $0.002.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.33.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,551,132 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.365 in its last earnings report, beating expectations of -$0.367. Following the earnings report the stock price went up 16.949%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (44.93% Upside)
$2.00 (44.93% Upside)
Hedge Fund Trend
Decreased
By 96.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $156.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.66%
12-Months-Change
Fundamentals
Return on Equity
-104.21%
Trailing 12-Months
Asset Growth
-55.59%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company focusing on the development of therapies designed to enhance the immune system's ability to eliminate cancer. The company's main product candidate, evorpacept (also known as ALX148), is a CD47-blocking therapeutic aimed at preventing cancer cells from evading the immune system. ALX Oncology operates within the biotechnology and pharmaceutical sectors, targeting various solid tumors and hematologic malignancies.
ALXO Company Deck
ALXO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong clinical results for evorpacept and promising progress for ALX2004. The company is well-funded and advancing its pipeline with optimism. However, there are challenges related to market positioning and historical concerns with ADCs that need addressing.View all ALXO earnings summariesALXO Stock 12 Month Forecast
Average Price Target
$2.00
▲(44.93% Upside)
Technical Analysis
Adverum Biotechnologies
―
InflaRx
―
Quince Therapeutics
―
Adagene
―
Context Therapeutics
―
Ownership Overview
2.98% Insiders
4.47% Mutual Funds
36.67% Other Institutional Investors
53.42% Public Companies and
Individual Investors